WallStSmart

America Movil SAB de CV ADR (AMX)vsWest Pharmaceutical Services Inc (WST)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

America Movil SAB de CV ADR generates 30596% more annual revenue ($943.64B vs $3.07B). WST leads profitability with a 16.1% profit margin vs 8.8%. AMX appears more attractively valued with a PEG of 1.17. AMX earns a higher WallStSmart Score of 69/100 (B-).

AMX

Strong Buy

69

out of 100

Grade: B-

Growth: 4.0Profit: 7.0Value: 10.0Quality: 4.0
Piotroski: 6/9Altman Z: 1.37

WST

Buy

55

out of 100

Grade: C-

Growth: 4.7Profit: 8.0Value: 4.7Quality: 7.3
Piotroski: 5/9Altman Z: 4.91
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

AMXUndervalued (+67.3%)

Margin of Safety

+67.3%

Fair Value

$72.07

Current Price

$24.76

$47.31 discount

UndervaluedFair: $72.07Overvalued
WSTSignificantly Overvalued (-256.8%)

Margin of Safety

-256.8%

Fair Value

$68.99

Current Price

$247.02

$178.03 premium

UndervaluedFair: $68.99Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

AMX5 strengths · Avg: 8.8/10
Free Cash FlowQuality
$42.68B10/10

Generating 42.7B in free cash flow

Market CapQuality
$70.61B9/10

Large-cap with strong market position

Return on EquityProfitability
20.5%9/10

Every $100 of equity generates 21 in profit

P/E RatioValuation
15.2x8/10

Attractively priced relative to earnings

Operating MarginProfitability
20.1%8/10

Strong operational efficiency at 20.1%

WST2 strengths · Avg: 9.0/10
Altman Z-ScoreHealth
4.9110/10

Safe zone — low bankruptcy risk

Operating MarginProfitability
21.6%8/10

Strong operational efficiency at 21.6%

Areas to Watch

AMX4 concerns · Avg: 3.0/10
Revenue GrowthGrowth
3.4%4/10

3.4% revenue growth

EPS GrowthGrowth
4.0%4/10

4.0% earnings growth

Price/BookValuation
72.8x2/10

Trading at 72.8x book value

Altman Z-ScoreHealth
1.372/10

Distress zone — elevated risk

WST3 concerns · Avg: 3.3/10
P/E RatioValuation
36.1x4/10

Premium valuation, high expectations priced in

EPS GrowthGrowth
2.1%4/10

2.1% earnings growth

PEG RatioValuation
2.892/10

Expensive relative to growth rate

Comparative Analysis Report

WallStSmart Research

Bull Case : AMX

The strongest argument for AMX centers on Free Cash Flow, Market Cap, Return on Equity. PEG of 1.17 suggests the stock is reasonably priced for its growth.

Bull Case : WST

The strongest argument for WST centers on Altman Z-Score, Operating Margin. Profitability is solid with margins at 16.1% and operating margin at 21.6%.

Bear Case : AMX

The primary concerns for AMX are Revenue Growth, EPS Growth, Price/Book. Debt-to-equity of 2.53 is elevated, increasing financial risk.

Bear Case : WST

The primary concerns for WST are P/E Ratio, EPS Growth, PEG Ratio.

Key Dynamics to Monitor

AMX profiles as a value stock while WST is a mature play — different risk/reward profiles.

WST carries more volatility with a beta of 1.18 — expect wider price swings.

WST is growing revenue faster at 7.5% — sustainability is the question.

AMX generates stronger free cash flow (42.7B), providing more financial flexibility.

Bottom Line

AMX scores higher overall (69/100 vs 55/100). Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

America Movil SAB de CV ADR

COMMUNICATION SERVICES · TELECOM SERVICES · USA

Amrica Mvil, SAB de CV provides telecommunications services in Latin America and internationally. The company is headquartered in Mexico City, Mexico.

Visit Website →

West Pharmaceutical Services Inc

HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA

West Pharmaceutical Services, Inc. is a designer and manufacturer of injectable pharmaceutical packaging and delivery systems. The company is headquartered in Exton, Pennsylvania.

Want to dig deeper into these stocks?